A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.
null Purwatinull BudionoBrian Eka Rachmannull YulistianiAndang Miatmokonull NasronudinSoroy LardoYongki Iswandi PurnamaMafidhatul LaelyIke RochmadTaufik IsmailSri WulandariDwi SetyawanAlfian Nur RosyidHerley Windo SetiawanPrastuti Asta WulaningrumTri Pudy AsmarawatiErika MarfianiShinta Karina YuniatiMuhammad Rabiul FuadiPepy Dwi Endraswarinull PurwaningsihEryk HendriantoDeya KarsariAristika DinaryantiNora ErtantiIgo Syaiful IhsanDisca Sandyakala PurnamaYuni IndrayaniPublished in: Biochemistry research international (2021)
The study findings suggest that the administration of lopinavir/ritonavir-doxycycline, lopinavir/ritonavir-azithromycin, and azithromycin-hydroxychloroquine as a dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment of mild to moderate COVID-19 cases. Further studies should involve observation of older patients with severe clinical symptoms in order to collate significant amounts of demographic data.
Keyphrases
- coronavirus disease
- double blind
- sars cov
- antiretroviral therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- clinical trial
- drug induced
- physical activity
- prognostic factors
- electronic health record
- randomized controlled trial
- respiratory syndrome coronavirus
- big data
- patient reported outcomes
- depressive symptoms
- patient reported